Richard Ducray

Title: Richard Ducray: Innovator in Antitumor Agents

Introduction

Richard Ducray is a notable inventor based in Reims, France. He has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds aimed at treating cancer. With a total of 3 patents, his work focuses on innovative solutions for combating tumor growth.

Latest Patents

Ducray's latest patents include groundbreaking compounds that serve as antitumor agents. One of his notable inventions is related to Pyrazolo[3,4-d]pyrimidine compounds, which are designed to produce an anti-proliferative effect. This effect is achieved by inhibiting the erbB2 receptor tyrosine kinase in warm-blooded animals, including humans. Another significant patent involves 4-(1H-indazol-5-yl-amino)-quinazoline compounds, which act as erbB receptor tyrosine kinase inhibitors for cancer treatment. These innovations reflect his commitment to advancing cancer therapies.

Career Highlights

Throughout his career, Richard Ducray has been associated with AstraZeneca AB, a leading global biopharmaceutical company. His work at AstraZeneca has allowed him to focus on the development of novel therapeutic agents that address critical health challenges.

Collaborations

Ducray has collaborated with esteemed colleagues, including Bernard Christophe Barlaam and Jason Grant Kettle. These partnerships have enhanced his research efforts and contributed to the successful development of his patented compounds.

Conclusion

Richard Ducray's contributions to the field of medicinal chemistry, particularly in the area of antitumor agents, highlight his innovative spirit and dedication to improving cancer treatment. His patents represent significant advancements in the fight against cancer, showcasing the importance of research and collaboration in the pharmaceutical industry.